{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"omics_type":["Unknown"],"volume":["17(1)"],"submitter":["Ding Z"],"funding":["Eddingpharm Co., Ltd., China","Shionogi"],"pubmed_abstract":["<h4>Purpose</h4>Probing efficacy and safety of lusutrombopag in Chinese chronic liver disease (CLD) and severe thrombocytopenia (PLT < 50 × 10<sup>9</sup>/L) patients undergoing elective invasive procedures.<h4>Methods</h4>In this double-blind, parallel-group phase 3 study, 66 patients with CLD and severe thrombocytopenia were randomized 2:1 to lusutrombopag or placebo arm treatment regimens for seven days at 9 centers in China. Responders (PLT ≥ 50 × 10<sup>9</sup>/L that increased to ≥ 20 × 10<sup>9</sup>/L from the baseline and not received rescue therapy for bleeding) on Day 8 (the day after seven-day treatment) were assessed. PLT ≥ 50 × 10<sup>9</sup>/L on or after Day 8 and within 2 days before invasive procedure (alternative criteria for not requiring platelet transfusion) were also"],"journal":["Hepatology international"],"pagination":["180-189"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC9895009"],"repository":["biostudies-literature"],"pubmed_title":["Lusutrombopag for thrombocytopenia in Chinese patients with chronic liver disease undergoing invasive procedures."],"pmcid":["PMC9895009"],"pubmed_authors":["Fu X","Zeng Y","Meng Z","Kano T","Wu H","Pan H","Yang W","Fan J","Kuang M","Shi G","Chen Y","Zou S","Liu C","Wang X","Ding Z","Sun H","Lin K","Hao C","Chen R","Yang S","Liang R","Zhou J"],"additional_accession":[]},"is_claimable":false,"name":"Lusutrombopag for thrombocytopenia in Chinese patients with chronic liver disease undergoing invasive procedures.","description":"<h4>Purpose</h4>Probing efficacy and safety of lusutrombopag in Chinese chronic liver disease (CLD) and severe thrombocytopenia (PLT < 50 × 10<sup>9</sup>/L) patients undergoing elective invasive procedures.<h4>Methods</h4>In this double-blind, parallel-group phase 3 study, 66 patients with CLD and severe thrombocytopenia were randomized 2:1 to lusutrombopag or placebo arm treatment regimens for seven days at 9 centers in China. Responders (PLT ≥ 50 × 10<sup>9</sup>/L that increased to ≥ 20 × 10<sup>9</sup>/L from the baseline and not received rescue therapy for bleeding) on Day 8 (the day after seven-day treatment) were assessed. PLT ≥ 50 × 10<sup>9</sup>/L on or after Day 8 and within 2 days before invasive procedure (alternative criteria for not requiring platelet transfusion) were also","dates":{"release":"2023-01-01T00:00:00Z","publication":"2023 Feb","modification":"2025-04-26T18:09:22.206Z","creation":"2025-02-19T03:30:30.863Z"},"accession":"S-EPMC9895009","cross_references":{"pubmed":["36258065"],"doi":["10.1007/s12072-022-10421-9"]}}